Document is current
Any future updates will be listed below
-
Authors
Wenzel, Julia G. https://orcid.org/0000-0002-1093-606X
Reichert, Markus
Zech, Hilmar
Wedemeyer, Friederike
Deeken, Friederike
Spitta, Gianna
Bach, Patrick
Lenz, Bernd
Ebner-Priemer, Ulrich W.
Kiefer, Falk
Rapp, Michael A.
Walter, Henrik
Heinz, Andreas
Banaschewski, Tobias
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (402170461 – TRR 265)
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 19 October 2024
First Online: 19 November 2024
Declarations
:
: Dr. Banaschewski served in an advisory or consultancy role for eye level, Infectopharm, Medice, Neurim Pharmaceuticals, Oberberg GmbH and Takeda. He received conference support or speaker’s fee by Janssen, Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. Dr. Ebner-Priemer has served as a consultant for Boehringer Ingelheim, including UE-P reports consultancy, and he has received a speaker honorarium from Angelini Pharma. No other disclosures were reported.
: This study has been approved on 09/17/2018 by the review boards of the local ethics committees at Heidelberg University (Ethics committee number: 2018-621N-MA) and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
: All participants gave their informed consent prior to their inclusion in the study and were compensated monetarily for their participation.
